Quality
- Home
- Quality
High standard injection process control
Precise temperature control ensures drug stability
Tah An’s injection production line is designed to meet high-specification requirements and has the ability to heat up to 90°C and cool down to 8°C throughout the entire process. This control technology is particularly critical for pet medications. It ensures stable drug efficacy and consistent manufacturing processes, and is a reflection of our commitment to quality.
High Performance Liquid Chromatography (HPLC)
2. Product content/valence analysis
3. Identification of active ingredients
4. Analysis of impurities or related substances
5. Application: Qualitative and quantitative analysis
Pet Cancer Drug ×
Taiwan Exclusive
Tah An is the first pharmaceutical manufacturer in Taiwan to engage in pet cancer drug development. Equipped with internationally compliant R&D facilities and explosion-proof safety systems, we can handle Class 1–4 hazardous chemicals, ensuring secure production of high-risk medicines. With leading technology, Tah An has become the top CDMO partner for veterinary oncology drugs in Taiwan.
Regulatory Strength
Tah An currently holds over 300 veterinary drug licenses for livestock and pets, making it the most license-complete animal pharmaceutical company in Taiwan. Its subsidiary, Yonglin Trading Co., is PIC/S GDP certified and holds 11 active pharmaceutical ingredient (API) licenses, leading the industry in both regulatory and trade capabilities.
Innovation and R&D × International Cooperation
Global Partnerships, Pet Pharma Breakthroughs
Tah An has a strong R&D team and advanced equipment. It has been deeply engaged in the innovative research and development of animal medicines for many years. In particular, it has successfully broken through technical bottlenecks in the field of pet cancer drugs, filled market gaps, and provided veterinary professionals with new and effective solutions.
Our research and development results have been recognized by the international market. In 2024, Tah An signed a memorandum of understanding (MOU) with Ainos, a Nasdaq-listed company in the United States, to jointly develop a new drug VELDONA® for animal testing, symbolizing that Taiwan's animal drug research and development technology has officially entered the international stage. In addition, we have also worked together with many listed pharmaceutical companies such as Gongxin KY, Yuzhan Pharmaceutical, and Jisheng Pharmaceutical to promote a number of new animal drug development projects, further strengthening Daan’s technology integration and global influence in the field of animal medicine.
